Subject Index

ACMG, see American College of Medical Genetics
Acute lymphoblastic leukemia (ALL)
classification 174
epidemiology 174
factors with influence on custom pediatric therapy
chromosomal translocations 175–177
host factors 177, 178
molecular genetics 175
ploidy 175
response to therapy 177
Adult hypolactasia, genetics 243, 244
ALL, see Acute lymphoblastic leukemia
Allergy
breastfeeding
elimination diet studies 168, 169
environmental factor interactions 163, 164
fatty acid content effects 170
immunologic factors 164–166
observational studies 158–163
protective factors 157, 158
infection effects 169, 170
prevention 246, 247
Toll-like receptor expression 122
American College of Medical Genetics (ACMG), recommended screening panels 82–89
Ampicillin, see Antibiotics
Antibiotics
gut decontamination of mice with norfloxacin and ampicillin
diet-induced obese mice and glucose tolerance improvement 134, 135
efficacy 129
ob/ob mice
body weight and fat effects 129, 130, 138
intestinal immune response effects 133
liver glucose and lipid metabolism effects 131–133
oral glucose tolerance response 130, 131
plasma endotoxemia effects 133, 134
neonatal intestinal microbiota considerations 20, 21
ART, see Assisted reproductive technology
Assisted reproductive technology (ART), epigenetic considerations 154, 155
Bifidobacteria, see Intestinal microbiota; Probiotics
Birth weight, risk of adult disease 3, 4, 9–12
Subject Index

Breastfeeding
  allergy
    elimination diet studies 168, 169
    environmental factor interactions 163, 164
    fatty acid content effects 170
    immunologic factors 164–166
    observational studies 158–163
    protective factors 157, 158
  growth patterns of infants 191, 202
  intestinal microbiota effects 21–23, 29, 30, 32, 212, 218–222, 227, 228
  lactation biology 206, 207
  microbiota transfer 227, 234, 237
  obesity studies 107
Breast milk
  bioactive proteins 192, 198, 203
  carbohydrates
    oligosaccharides
      analysis 209–212, 220
      changes over time 218
      personalization of infant feeding 216, 222, 223
      selective microbial fermentation 213–215
      overview 193, 201, 208, 209
  energy density 194, 195
  functions 207, 208
  genomics studies of components 206
  lipids 193, 194
  micronutrients 195, 196
  protein concentration 191
Cancer, see Acute lymphoblastic leukemia; Osteosarcoma
Carnitine, nutritional therapy 75–78
CD, see Celiac disease
CD14, breast milk content and allergy protection 166
Celiac disease (CD)
  genetics 244, 245
  prevention 245, 249, 250
  Swedish epidemic 244, 245, 250
Colostrum, see Breast milk
Computed tomography (CT), body composition 53
CpG islands, see Epigenetics
CT, see Computed tomography
CYP21A2, individual variation of expression 143, 144
Developmental plasticity
  definition 3
  pathways to obesity and insulin resistance
    fetal hyperinsulinemia pathway 7
    infant overnutrition 7, 8
    mismatch pathway 6, 7
    risk of adult disease 3, 4
    sex differences 10
Diabetes type 1
  genotypes 249
  prevention 245, 246
Dietary recommendations, establishment 240
DNA methylation, see Epigenetics
DNMT1, epigenetic regulation 152
Energy balance, obesity 97, 99, 104
Epigenetics
  assisted reproductive technology considerations 154, 155
  CpG islands 142, 152, 153
  critical windows 151
  early programming 146, 147
  gene regulation 142
  individual variation 142–146
  mechanisms 153, 154
  microbial influences 154
  sources of individual variation 147, 148
FADS1
  function 38
  single nucleotide polymorphisms implications 41, 43
  polyunsaturated fatty acid status 38–41
FADS2
  function 38
  single nucleotide polymorphisms implications 41, 43
  polyunsaturated fatty acid status 38–41
Familial hypercholesterolemia (FH), genetics 243
Fatty acids, see Polyunsaturated fatty acids
FH, see Familial hypercholesterolemia
Folate, neural tube defect prevention 251, 252
Formula, see Infant formula
FTO, alleles and obesity 3, 100
<table>
<thead>
<tr>
<th>Subject Index</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gut colonization, see Intestinal microbiota</td>
</tr>
<tr>
<td>H19, individual variation of expression 144</td>
</tr>
<tr>
<td>Hypercholesterolemia, see Familial hypercholesterolemia</td>
</tr>
<tr>
<td>Hypolactasia, see Adult hypolactasia</td>
</tr>
<tr>
<td>IGFs, see Insulin-like growth factors</td>
</tr>
<tr>
<td>Immune function, see also Intestinal microbiota</td>
</tr>
<tr>
<td>feeding and antigenic stimulation 114, 115</td>
</tr>
<tr>
<td>fetal immune structure and function in gut 112–114</td>
</tr>
<tr>
<td>gut barrier function 116</td>
</tr>
<tr>
<td>inoculation at birth 114</td>
</tr>
<tr>
<td>molecular mechanisms of colonization response 118–120</td>
</tr>
<tr>
<td>probiotic effects 123, 124, 229</td>
</tr>
<tr>
<td>thymic stromal lymphoprotein 117, 118</td>
</tr>
<tr>
<td>Immunoglobulin A</td>
</tr>
<tr>
<td>addition to formula 201</td>
</tr>
<tr>
<td>breast milk 192, 198</td>
</tr>
<tr>
<td>Inborn errors of metabolism, see also specific diseases</td>
</tr>
<tr>
<td>nutritional therapy 69–72</td>
</tr>
<tr>
<td>screening of newborns</td>
</tr>
<tr>
<td>American College of Medical Genetics recommended panels 82–89</td>
</tr>
<tr>
<td>high throughput screening prospects 92</td>
</tr>
<tr>
<td>tandem mass spectrometry 81, 82, 89–91, 94, 95</td>
</tr>
<tr>
<td>types 56–64</td>
</tr>
<tr>
<td>Infant formula</td>
</tr>
<tr>
<td>age-specific product rationale 196, 200</td>
</tr>
<tr>
<td>bioactive proteins 192, 201</td>
</tr>
<tr>
<td>carbohydrates 193</td>
</tr>
<tr>
<td>energy density 194, 195</td>
</tr>
<tr>
<td>growth patterns of infants 191, 202</td>
</tr>
<tr>
<td>lipids 193, 194</td>
</tr>
<tr>
<td>microbiota influences 199</td>
</tr>
<tr>
<td>micronutrients 195, 196</td>
</tr>
<tr>
<td>omega-3 fatty acids 201</td>
</tr>
<tr>
<td>protein concentration 191, 192</td>
</tr>
<tr>
<td>Insulin-like growth factors (IGFs)</td>
</tr>
<tr>
<td>breast milk 203</td>
</tr>
<tr>
<td>IGF2 individual variation of expression 144</td>
</tr>
<tr>
<td>Insulin resistance</td>
</tr>
<tr>
<td>developmental pathways</td>
</tr>
<tr>
<td>fetal hyperinsulinemia pathway 7</td>
</tr>
<tr>
<td>infant overnutrition 7, 8</td>
</tr>
<tr>
<td>mismatch pathway 6, 7</td>
</tr>
<tr>
<td>gut decontamination effects</td>
</tr>
<tr>
<td>diet-induced obese mice and glucose tolerance improvement 134, 135</td>
</tr>
<tr>
<td>ob/ob mice 130, 131</td>
</tr>
<tr>
<td>Intestinal microbiota</td>
</tr>
<tr>
<td>bacteria sources 18–20, 114</td>
</tr>
<tr>
<td>Bifidobacterium infantalis genome sequencing 219</td>
</tr>
<tr>
<td>breast milk microbiota transfer 227, 234, 237</td>
</tr>
<tr>
<td>breastfeeding effects 21–23, 29, 30, 32, 212, 218–222, 227, 228</td>
</tr>
<tr>
<td>cesarean section versus vaginal delivery effects 20, 114</td>
</tr>
<tr>
<td>epithelial interactions 116, 117</td>
</tr>
<tr>
<td>gut decontamination of mice with norfloxacin and ampicillin</td>
</tr>
<tr>
<td>diet-induced obese mice and glucose tolerance improvement 134, 135</td>
</tr>
<tr>
<td>efficacy 129</td>
</tr>
<tr>
<td>ob/ob mice body weight and fat effects 129, 130, 138</td>
</tr>
<tr>
<td>intestinal immune response effects 133</td>
</tr>
<tr>
<td>liver glucose and lipid metabolism effects 131–133</td>
</tr>
<tr>
<td>oral glucose tolerance response 130, 131</td>
</tr>
<tr>
<td>plasma endotoxemia effects 133, 134</td>
</tr>
<tr>
<td>home environment and lifestyle effects 23, 24</td>
</tr>
<tr>
<td>infant formula influences 199</td>
</tr>
<tr>
<td>metabolic function 128</td>
</tr>
<tr>
<td>milk oligosaccharide and selective microbial fermentation 213–215</td>
</tr>
<tr>
<td>molecular mechanisms of immune response 118–120</td>
</tr>
<tr>
<td>neonatal intensive care unit considerations 20, 21</td>
</tr>
<tr>
<td>neonates 226</td>
</tr>
</tbody>
</table>
Subject Index

Intestinal microbiota (continued)
patterns
  consequences of Western pattern 25
  non-Western societies 24, 25
  sequential establishment 13–18
  succession 228, 229, 236

Lactoferrin, milk 192

Magnetic resonance imaging (MRI)
  body composition 52, 53
  functional magnetic resonance
  imaging and nutrition 54
Magnetic resonance spectroscopy (MRS)
  metabolic diseases 77, 78
  sensitivity 516
Maple syrup urine disease (MSUD)
  dietary management 67, 68
  individual differences in severity 78
Mass spectrometry, see Tandem mass spectrometry
Metabolic disorders, see Inborn errors of metabolism
Metabolic profiling
  metabolic diseases 56–64
  overview 55, 56
  tandem mass spectrometry for
  metabolic disease screening on
  newborns 81, 82, 89–91, 94, 95
Mismatch pathway, obesity and insulin resistance 6, 7
MRI, see Magnetic resonance imaging
MRS, see Magnetic resonance spectroscopy
MSUD, see Maple syrup urine disease

Neural tube defect (NTD), prevention 251, 252
Norfloxacin, see Antibiotics
NTD, see Neural tube defect
Nutrient requirements, establishment 240
Nutrigenetics 241, 242
Nutrigenomics 241, 242
Nutritional therapy
  carnitine 75–78
  maple syrup urine disease 67, 68
  metabolic disease types 56–64, 69–72
  phenylketonuria 56, 65

Obesity
  body weight control 98–100
  breastfeeding studies 107
developmental aspects of energy expenditure 104
developmental pathways
  fetal hyperinsulinemia pathway 7
  infant overnutrition 7, 8, 109, 110
  mismatch pathway 6, 7
  energy balance 97, 99, 104
  family environment modification 103, 104
  genetics 99–102, 108, 109
  hormonal resistance to weight loss 99
  modifiable risk factors 102, 103
  pregnancy 9, 10
Osteosarcoma
  epidemiology 179
  ethics of prognostication without treatment options 186, 188
  expression profiling 180, 181, 186
  multi-gene classifier prediction of chemotherapy response 181–183, 186, 187
  prognostic factors 179, 180
Phenylketonuria (PKU)
  dietary management 56, 65
  gene defects 242, 243
  individual differences in severity 79, 243
  omega-3 fatty acid supplementation 46, 49
PKU, see Phenylketonuria
Polyunsaturated fatty acids (PUFAs)
  long-chain fatty acid metabolism 35–38
  single nucleotide polymorphisms and status
    FADS1 38–41
    FADS2 38–41
  implications 41, 43
Prebiotics
  allergy prevention 246, 247
  definition 123
Probiotics
  benefits 224, 225, 229, 230
  definition 225, 235
  immune effects 123, 124, 229
  prospects for study 231
  regulation 235, 236
  types 225, 226, 233
PUFAs, see Polyunsaturated fatty acids
Screening, see Inborn errors of metabolism
Single nucleotide polymorphisms (SNPs)
nutrigenetics 241, 242
polyunsaturated fatty acid metabolism
  \( FADS1 \) 38–41
  \( FADS2 \) 38–41
  implications 41, 43

Tandem mass spectrometry
  metabolic disease screening on newborns 81, 82, 89–91, 94, 95
  milk oligosaccharide analysis 211, 212
TGF-\( \beta \), see Transforming growth factor-\( \beta \)
Thrifty genotype hypothesis 2, 3
Thymic stromal lymphoprotein (TSLP), immune function 117, 118

TLRs, see Toll-like receptors
Toll-like receptors (TLRs)
  expression in allergy 122
  human milk 115
  TLR4 function 128
Transforming growth factor-\( \beta \) (TGF-\( \beta \)),
  breast milk content and allergy protection 164, 165
TSLP, see Thymic stromal lymphoprotein
Twins, epigenetic variations between monozygotic twins 144, 146
Zinc, colostrum concentration 196